Alan Ashworth

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7873378/publications.pdf

Version: 2024-02-01

61	31,838	57758	123424
papers	citations	44 h-index	61 g-index

67	67	67	35234
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917-921.	27.8	5,595
2	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	27.8	3,542
3	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers. New England Journal of Medicine, 2009, 361, 123-134.	27.0	3,312
4	Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378, 789-792.	27.8	3,230
5	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158.	12.6	1,826
6	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
7	Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews Cancer, 2004, 4, 814-819.	28.4	1,477
8	Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer Research, 2006, 66, 8109-8115.	0.9	1,172
9	BRCAness revisited. Nature Reviews Cancer, 2016, 16, 110-120.	28.4	976
10	Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008, 451, 1111-1115.	27.8	894
11	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology, 2010, 28, 2512-2519.	1.6	877
12	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 2018, 24, 628-637.	30.7	649
13	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	28.9	459
14	BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency. Clinical Cancer Research, 2013, 19, 5003-5015.	7.0	416
15	Genetic Interactions in Cancer Progression and Treatment. Cell, 2011, 145, 30-38.	28.9	380
16	Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell, 2018, 175, 1958-1971.e15.	28.9	378
17	Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nature Medicine, 2013, 19, 1381-1388.	30.7	371
18	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nature Communications, 2018, 9, 1849.	12.8	310

#	Article	IF	Citations
19	Synthetic lethal therapies for cancer: whatâ€™s next after PARP inhibitors?. Nature Reviews Clinical Oncology, 2018, 15, 564-576.	27.6	303
20	Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery, 2020, 19, 23-38.	46.4	295
21	A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer. Clinical Cancer Research, 2010, 16, 6159-6168.	7.0	287
22	Secondary mutations in <scp>BRCA2</scp> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	4.5	287
23	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature Communications, 2016, 7, 13837.	12.8	272
24	PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	8.2	222
25	PARP inhibitor combination therapy. Critical Reviews in Oncology/Hematology, 2016, 108, 73-85.	4.4	175
26	Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discovery, 2020, 10, 351-370.	9.4	162
27	ADPâ€ribosyltransferases, an update on function and nomenclature. FEBS Journal, 2022, 289, 7399-7410.	4.7	150
28	A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity. PLoS ONE, 2013, 8, e61520.	2.5	147
29	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	28.9	135
30	MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene, 1999, 18, 6981-6988.	5.9	132
31	A Short Pseudoautosomal Region in Laboratory Mice. Genome Research, 2001, 11, 1826-1832.	5.5	120
32	The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer. Molecular Cell, 2015, 58, 690-698.	9.7	117
33	Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Science Advances, 2021, 7, .	10.3	100
34	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Reports, 2016, 14, 2490-2501.	6.4	97
35	Evolutionary rate of a gene affected by chromosomal position. Current Biology, 1999, 9, 987-S3.	3.9	94
36	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	1.3	90

#	Article	IF	Citations
37	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British Journal of Cancer, 2017, 117, 113-123.	6.4	84
38	Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Reports, 2018, 22, 1875-1888.	6.4	83
39	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
40	Complementation of byrl in fission yeast by mammalian MAP kinase kinase requires coexpression of Raf kinase. Nature, 1993, 364, 349-352.	27.8	76
41	Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Molecular Cancer Therapeutics, 2016, 15, 1472-1484.	4.1	73
42	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Molecular Cancer Therapeutics, 2017, 16, 2022-2034.	4.1	66
43	A protein interaction landscape of breast cancer. Science, 2021, 374, eabf3066.	12.6	66
44	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE, 2016, 11, e0149099.	2.5	60
45	Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Molecular Cancer Therapeutics, 2015, 14, 865-876.	4.1	52
46	ATR Is a Therapeutic Target in Synovial Sarcoma. Cancer Research, 2017, 77, 7014-7026.	0.9	43
47	A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Scientific Reports, 2019, 9, 201.	3.3	38
48	Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 3080-3081.	1.6	31
49	Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. Journal of Medicinal Chemistry, 2019, 62, 5330-5357.	6.4	26
50	The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling. Oncotarget, 2014, 5, 12126-12140.	1.8	26
51	Anin vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells. International Journal of Cancer, 1995, 62, 297-302.	5.1	24
52	The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature. Science Advances, 2022, 8, .	10.3	24
53	Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. Nature Communications, 2018, 9, 2016.	12.8	22
54	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation, 2018, 128, 1671-1687.	8.2	19

#	Article	IF	Citations
55	Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget, 2015, 6, 10746-10758.	1.8	16
56	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. Scientific Data, 2017, 4, 170020.	5.3	14
57	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. Scientific Reports, 2018, 8, 10614.	3.3	13
58	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget, 2015, 6, 10994-11008.	1.8	13
59	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 2021, 81, 1076-1086.	0.9	10
60	A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor. Molecular Cancer Therapeutics, 2022, 21, 1076-1089.	4.1	8
61	Hypoxia Is a Dominant Remodeler of the Effector TÂCell Surface Proteome Relative to Activation and Regulatory T Cell Suppression. Molecular and Cellular Proteomics, 2022, 21, 100217.	3.8	5